Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 181

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 181
---
$46,052 

130

As of and for Year Ended December 31, 2023Maturity          (In Years)Amortized CostUnrealized GainsUnrealized LossesFair ValueMoney market funds$61,034 $— $— $61,034 U.S. government treasury billsLess than 119,441 17 — 19,458 Commercial paperLess than 18,712 6 (1)8,717 Corporate bondsLess than 113,438 10 (1)13,447 Government agencyLess than 15,486 — (4)5,482 Total$108,111 $33 $(6)$108,138 

5. Accrued Liabilities

Details of accrued liabilities are presented as follows (in thousands):As of December 31,20242023Accrued professional fees$5,157 $2,504 Accrued salaries and payroll2,681 $1,590 Accrued restructuring charges1,333 — Accrued bonus64 3,081 Accrued contract manufacturing2,597 4,315 Accrued clinical977 1,416 Accrued other - sales related1,188 772 Accrued other650 628 Total accrued liabilities$14,647 $14,306 

6. Operating Leases

In April 2019, the Company entered into a twenty-eight month facility lease agreement for office space in Pacific Palisades, California (the “Pacific Palisades Lease”). The Pacific Palisades Lease commenced on May 1, 2019, included four months of rent abatement and a rent escalation clause and was set to expire on August 31, 2021. In August 2021, the Company exercised its option to extend the term of the Pacific Palisades Lease for an additional three-year period and entered into an amendment to the lease agreement (the “Pacific Palisades Lease Amendment”). Pursuant to the Pacific Palisades Lease Amendment, the Company and the landlord agreed to extend the term for an additional period of three (3) years and six (6) months, until February 28, 2025, with an option to renew for an additional three (3) years in accordance with the terms of the lease. The Company did not exercise the option to renew. Included in the Pacific Palisades Lease Amendment